Integra LifeSciences Reports Strong 2024 Results and Provides Positive Outlook for 2025

Integra LifeSciences Holdings Corporation (NASDAQ: IART) recently reported its financial results for the fourth quarter and full year 2024, showcasing strong performance and providing positive guidance for 2025. The company's reported revenues for the fourth quarter were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter of 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per diluted share were $0.97, compared to $0.89 in the fourth quarter 2023.

For the full year 2024, reported revenues were $1,610.5 million, representing an increase of 4.5% on a reported basis and a decrease of 1.3% on an organic basis compared to full-year 2023. GAAP earnings per diluted share were $(0.09), compared to $0.84 in 2023. Adjusted earnings per diluted share were $2.56, compared to $3.10 in 2023.



Key drivers behind these results include strong demand for the company's differentiated portfolio of leading brands, continued progress in expanding the company's global presence, critical investments in capacity and supply reliability, successful integration of the Acclarent acquisition, strong market uptake of CereLink, and advancements in regulatory submissions for DuraSorb and SurgiMend.

Integra LifeSciences' CEO, Mojdeh Poul, expressed confidence in the company's ability to address quality system challenges and position the company for long-term, sustainable growth. She highlighted the company's competitive strengths, differentiated technologies, commercial expertise, and global presence as key factors driving growth and innovation.

Looking ahead to 2025, Integra LifeSciences expects to achieve revenue growth and improve profitability by enhancing its quality system, streamlining processes, and leveraging its competitive strengths. The company's financial guidance reflects its commitment to growth and long-term success, with a focus on driving innovation and delivering value to customers, patients, and shareholders.

In conclusion, Integra LifeSciences' strong financial performance in 2024, coupled with its positive outlook for 2025, demonstrates the company's commitment to growth, innovation, and long-term success. By leveraging its competitive strengths and differentiated technologies, Integra LifeSciences is poised to unlock new opportunities for innovation and deliver greater value to its customers, patients, and shareholders.